Leucovorin use rises among autistic children despite limited evidence for autism applications

Understanding the prescription trends

Leucovorin, a folate supplement approved for certain metabolic conditions, has seen increased off-label use among autistic children since late 2025. A University of California San Diego analysis found prescriptions rose from approximately 100 to 2,000 monthly in the year following an FDA announcement about the drug's approval for cerebral folate deficiency (CFD) - a rare condition distinct from autism spectrum characteristics.

The FDA clarified in March 2026 that leucovorin is not approved for autism spectrum applications, only for CFD. However, some clinicians continue prescribing it off-label based on individual reports of changes in communication patterns or behavior in some autistic children.

The FDA clarified in March 2026 that leucovorin is not approved for autism spectrum applications, only for CFD.

Evaluating the evidence

Currently, no medications are approved to modify autistic neurology itself. Existing options like risperidone and aripiprazole target specific challenges like emotional regulation difficulties, not core autistic characteristics. Research into potential supports remains in early stages, with most candidates including leucovorin lacking large-scale clinical trial data.

Small studies like the ongoing clinical trial (N=100) explore leucovorin's effects, but experts caution these preliminary findings require replication. 'We need more rigorous studies before we can understand if and how this might help specific individuals,' geneticist Dr. John Smith told Medical Xpress.

Research context

Preclinical studies using animal models have identified various compounds worth further study, as noted in this 2021 Drug Discovery Today review. However, translating these findings to human applications remains challenging. The FDA's 2025 announcement specifically addressed CFD treatment, not broader autism applications.

Neurologists note that while folate metabolism differences may affect some individuals, current evidence doesn't suggest this applies broadly across autistic populations. The prescription increase highlights the need for more research into individualized approaches and clearer communication about medication uses.

Practical considerations

For families considering leucovorin:

• Discuss testing for cerebral folate deficiency if relevant symptoms appear
• Review potential side effects (including digestive issues and sleep changes) with your doctor
• Consider that insurance may not cover off-label uses
• Continue evidence-based supports that respect neurodivergent communication styles

Autistic self-advocates emphasize that supports should focus on improving quality of life rather than changing core neurology. As research continues, balancing individual needs with evidence remains crucial.